141 related articles for article (PubMed ID: 34731765)
21. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
22. Validation of a P2Y
Amann M; Ferenc M; Valina CM; Bömicke T; Stratz C; Leggewie S; Trenk D; Neumann FJ; Hochholzer W
Platelets; 2016 Nov; 27(7):668-672. PubMed ID: 27065056
[TBL] [Abstract][Full Text] [Related]
23. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM
Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
[TBL] [Abstract][Full Text] [Related]
24. In Vitro Binding of [³H]PSB-0413 to P2Y₁₂ Receptors.
Dupuis A; Heim V; Ohlmann P; Gachet C
Curr Protoc Pharmacol; 2015 Dec; 71():1.35.1-1.35.19. PubMed ID: 26646192
[TBL] [Abstract][Full Text] [Related]
25. P2Y12 receptor: platelet thrombus formation and medical interventions.
Moheimani F; Jackson DE
Int J Hematol; 2012 Nov; 96(5):572-87. PubMed ID: 23054651
[TBL] [Abstract][Full Text] [Related]
26. Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y₁ and P2Y₁₂ receptors.
Aslam M; Sedding D; Koshty A; Santoso S; Schulz R; Hamm C; Gündüz D
Thromb Res; 2013 Nov; 132(5):548-57. PubMed ID: 24071464
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
[TBL] [Abstract][Full Text] [Related]
28. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
29. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis.
Liu Z; Xiang Q; Mu G; Xie Q; Zhou S; Wang Z; Chen S; Hu K; Gong Y; Jiang J; Cui Y
Platelets; 2020; 31(1):3-14. PubMed ID: 30744477
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
Tu W; Fan J; Zhang H; Xu G; Liu Z; Qu J; Yang F; Zhang L; Luan T; Yuan J; Gong A; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2014 Jan; 24(1):141-6. PubMed ID: 24332627
[TBL] [Abstract][Full Text] [Related]
31. P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Liverani E; Rico MC; Tsygankov AY; Kilpatrick LE; Kunapuli SP
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):961-71. PubMed ID: 27055904
[TBL] [Abstract][Full Text] [Related]
32. Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.
Mingant F; Didier R; Gilard M; Martin F; Nicol PP; Ugo V; Lippert E; Galinat H
Platelets; 2018 May; 29(3):257-264. PubMed ID: 29580115
[TBL] [Abstract][Full Text] [Related]
33. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Jakubowski JA; Zhou C; Egan B; Wells M; Kotob-Yahfoufi M; Sugidachi A; Dahlen JR
Platelets; 2011; 22(8):619-25. PubMed ID: 21639823
[TBL] [Abstract][Full Text] [Related]
34. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
35. Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane.
Rabani V; Montange D; Meneveau N; Davani S
Platelets; 2018 Nov; 29(7):709-715. PubMed ID: 29020490
[TBL] [Abstract][Full Text] [Related]
36. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
37. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
38. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism.
Zhang S; Hu L; Du H; Guo Y; Zhang Y; Niu H; Jin J; Zhang J; Liu J; Zhang X; Kunapuli SP; Ding Z
Thromb Haemost; 2010 Oct; 104(4):845-57. PubMed ID: 20806121
[TBL] [Abstract][Full Text] [Related]
39. State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.
Zetterberg F; Svensson P
Bioorg Med Chem Lett; 2016 Jun; 26(12):2739-2754. PubMed ID: 27133596
[TBL] [Abstract][Full Text] [Related]
40. A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention.
Jang J; Lim J; Chang K; Kim Y; Kim M; Park HI; Kim J; Shin S
J Clin Lab Anal; 2012 Jul; 26(4):262-6. PubMed ID: 22811359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
